drugset / Trial / NCT04667039
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a randomized, double-blind, comparative, parallel group study of the efficacy, safety pharmacokinetics, and immunogenicity of GNR-067 and Lucentis® in patients with neovascular (wet) age-related macular degeneration.
Timeline
- Start
- 2022-03-20
- Primary completion
- 2024-08-15
- Completion
- 2024-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GNR-067 | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |